These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31848027)

  • 21. Case 30-2019: A 65-Year-Old Woman with Lung Cancer and Chest Pain.
    Guiney TE; Lopes MS; Kalra MK; Mooradian MJ; Neilan TG; Stone JR
    N Engl J Med; 2019 Sep; 381(13):1268-1277. PubMed ID: 31553841
    [No Abstract]   [Full Text] [Related]  

  • 22. Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.
    Gokozan HN; Friedman JD; Schmaier AH; Downes KA; Farah LA; Reeves HM
    Clin Lung Cancer; 2019 Sep; 20(5):e560-e563. PubMed ID: 31311716
    [No Abstract]   [Full Text] [Related]  

  • 23. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma.
    Chen Q; Huang DS; Zhang LW; Li YQ; Wang HW; Liu HB
    Clin Toxicol (Phila); 2018 Jul; 56(7):667-671. PubMed ID: 29126352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
    Baldini E; Lunghi A; Cortesi E; Turci D; Signorelli D; Stati V; Melotti B; Ricciuti B; Frassoldati A; Romano G; Ceresoli GL; Illiano A; Verderame F; Fasola G; Ricevuto E; Marchetti P; Pinto C; Cartenì G; Scotti V; Tibaldi C; Fioretto L; Giannarelli D
    Lung Cancer; 2020 Feb; 140():59-64. PubMed ID: 31881412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
    Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV
    Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis.
    So H; Ikeguchi R; Kobayashi M; Suzuki M; Shimizu Y; Kitagawa K
    J Neurol Sci; 2019 Apr; 399():97-100. PubMed ID: 30798111
    [No Abstract]   [Full Text] [Related]  

  • 27. Early detection and management of immune-related myocarditis: Experience from a case with advanced squamous cell lung carcinoma.
    Tu L; Liu J; Li Z; Liu Y; Luo F
    Eur J Cancer; 2020 May; 131():5-8. PubMed ID: 32248072
    [No Abstract]   [Full Text] [Related]  

  • 28. Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy.
    Nishimura T; Ninomiya K; Nakashima M; Akagi S; Kuribayashi T; Higo H; Hotta K; Maeda Y; Ito H; Kiura K
    Intern Med; 2023 May; 62(9):1319-1322. PubMed ID: 36130891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma.
    Sato K; Ono T; Sato F; Kawahara A; Azuma K; Kawaguchi T; Akiba J; Umeno H
    Oral Oncol; 2020 Feb; 101():104366. PubMed ID: 31300273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors.
    Ji C; Roy MD; Golas J; Vitsky A; Ram S; Kumpf SW; Martin M; Barletta F; Meier WA; Hooper AT; Sapra P; Khan NK; Finkelstein M; Guffroy M; Buetow BS
    Clin Cancer Res; 2019 Aug; 25(15):4735-4748. PubMed ID: 31085720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lung squamous cell carcinoma responding to nivolumab retreatment six years after initial treatment: A case report.
    Kono K; Nakashima K; Tsubata Y; Amano Y; Kawakado K; Yanagawa T; Isobe T
    Thorac Cancer; 2024 Aug; 15(22):1714-1717. PubMed ID: 38956899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
    Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
    Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC.
    Callens R; Tamsin A; van Zandweghe L
    J Thorac Oncol; 2019 Mar; 14(3):e49-e50. PubMed ID: 30782382
    [No Abstract]   [Full Text] [Related]  

  • 34. Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
    Swami U; Smith M; Zhang J
    J Thorac Oncol; 2018 Sep; 13(9):e183-e184. PubMed ID: 30166022
    [No Abstract]   [Full Text] [Related]  

  • 35. [Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report].
    Miyashita K; Kajikawa H; Utsunomiya T; Hosaka M; Naito Y; Tomimoto H
    Rinsho Shinkeigaku; 2020 Nov; 60(11):768-772. PubMed ID: 33115992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab.
    Rouyer L; Bursztejn AC; Charbit L; Schmutz JL; Moawad S
    Eur J Dermatol; 2018 Jun; 28(3):380-381. PubMed ID: 29952288
    [No Abstract]   [Full Text] [Related]  

  • 37. Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.
    Facchinetti F; Gnetti L; Caruana P; Fornaroli F; Luigi de'Angelis G; Sabato M; Ferri L; Cosenza A; Bordi P; Tiseo M
    Clin Lung Cancer; 2018 Sep; 19(5):e591-e596. PubMed ID: 29801705
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report.
    Cortellini A; Verna L; Porzio G; Bozzetti F; Palumbo P; Masciocchi C; Cannita K; Parisi A; Brocco D; Tinari N; Ficorella C
    Thorac Cancer; 2019 Feb; 10(2):347-351. PubMed ID: 30600905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature.
    Wu L; Yu Y; Zhou J; Wang X; Li J; Wang Y
    Immunotherapy; 2020 Sep; 12(13):957-964. PubMed ID: 32686549
    [No Abstract]   [Full Text] [Related]  

  • 40. Nivolumab-induced Limbic Encephalitis with Anti-Hu Antibody in a Patient With Advanced Pleomorphic Carcinoma of the Lung.
    Matsuoka H; Kimura H; Koba H; Tambo Y; Ohkura N; Hara J; Sone T; Kasahara K
    Clin Lung Cancer; 2018 Sep; 19(5):e597-e599. PubMed ID: 29857970
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.